Ítem
Acceso Abierto

Esquemas de rituximab y conteo de linfocitos en pacientes con Neuromielitis óptica: revisión sistemática

Mostrar el registro sencillo de la publicación
dc.contributor.advisorOrtiz Salas, Paola Andrea
dc.contributor.advisorHernández, Gilma
dc.contributor.gruplacEducación Médica y en Ciencias de la Salud
dc.creatorQuilagüy Jiménez, María Alejandra
dc.creator.degreeEspecialista en Neurología
dc.creator.degreeLevelMaestría
dc.date.accessioned2025-11-25T13:21:02Z
dc.date.available2025-11-25T13:21:02Z
dc.date.created2025-09-30
dc.descriptionLa neuromielitis óptica (NMO) es una enfermedad inflamatoria y autoinmune del sistema nervioso central caracterizada por recaídas severas y discapacidad acumulativa. El rituximab (RTX), un anticuerpo monoclonal dirigido contra linfocitos B, se ha consolidado como una de las principales opciones terapéuticas. Sin embargo, persiste una marcada heterogeneidad en los esquemas de dosificación y en los criterios de seguimiento, lo que limita la estandarización de su uso. En este contexto, la citometría de flujo emerge como una herramienta útil para monitorizar la depleción y repoblación de linfocitos B, particularmente las subpoblaciones CD19⁺ y CD27⁺, con potencial impacto en la personalización del tratamiento.
dc.description.abstractNeuromyelitis optica (NMO) is an inflammatory and autoimmune disease of the central nervous system characterized by severe relapses and cumulative disability. Rituximab (RTX), a monoclonal antibody directed against B lymphocytes, has become one of the main therapeutic options. However, there remains significant heterogeneity in dosing regimens and monitoring criteria, which limits the standardization of its use. In this context, flow cytometry emerges as a useful tool to monitor B-cell depletion and repopulation, particularly the CD19⁺ and CD27⁺ subpopulations, with potential impact on treatment personalization.
dc.format.extent28 pp
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.48713/10336_47032
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/47032
dc.language.isospa
dc.publisherUniversidad del Rosario
dc.publisher.departmentEscuela de Medicina y Ciencias de la Salud-Especialización en Neurología
dc.publisher.programEspecialización en Neurología
dc.relation.relatedhttps://doi.org/10.1016/j.msard.2025.106798
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma.spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.source.bibliographicCitationGlisson CC. Neuromyelitis Optica Spectrum Disorders (NMOSD). Curr Treat Options Neurol. 2022;24(6):241-251. doi:10.1007/S11940-022-00709-4/TABLES/1
dc.source.bibliographicCitationLu Q, Luo J, Hao H, et al. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;40:101933. doi:10.1016/J.MSARD.2020.101933
dc.source.bibliographicCitationKim SH, Huh SY, Lee SJ, Joung AR, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110-1117. doi:10.1001/jamaneurol.2013.3071
dc.source.bibliographicCitationBennett JL, O’Connor KC, Bar-Or A, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol NeuroInflammation. 2015;2(3):e104. doi:10.1212/NXI.0000000000000104
dc.source.bibliographicCitationKim SH, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68(11):1412-1420. doi:10.1001/archneurol.2011.154
dc.source.bibliographicCitationCarlsson O, Jonsson DI, Brundin L, Iacobaeus E. Relapses and Serious Infections in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab: A Swedish Single-Center Study. J Clin Med 2024, Vol 13, Page 355. 2024;13(2):355. doi:10.3390/JCM13020355
dc.source.bibliographicCitationNovi G, Bovis F, Capobianco M, et al. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2019;36:101430. doi:10.1016/J.MSARD.2019.101430
dc.source.bibliographicCitationRual C, Biotti D, Lepine Z, et al. 2 grams versus 1 gram rituximab as maintenance schedule in multiple sclerosis, neuromyelitis optica spectrum disorders and related diseases: What B-cell repopulation data tell us. Mult Scler Relat Disord. 2023;71:104563. doi:10.1016/J.MSARD.2023.104563
dc.source.bibliographicCitationCabre P, Mejdoubi M, Jeannin S, et al. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. J Neurol. 2018;265(4):917-925. doi:10.1007/S00415-018-8771-5/METRICS
dc.source.bibliographicCitationCao S, Wang X, Ji X, et al. B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study. Mult Scler Relat Disord. 2023;70:104524. doi:10.1016/J.MSARD.2023.104524
dc.source.bibliographicCitationZhang C, Liu R, Gao B, et al. Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder. J Neuroimmunol. 2024;387:578285. doi:10.1016/J.JNEUROIM.2024.578285
dc.source.bibliographicCitationCohen M, Romero G, Bas J, et al. Monitoring CD27 + memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study. J Neurol Sci. 2017;373:335-338. doi:10.1016/j.jns.2017.01.025
dc.source.bibliographicCitationCree BAC, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270-1272. doi:10.1212/01.WNL.0000159399.81861.D5
dc.source.bibliographicCitationEllrichmann G, Bolz J, Peschke M, et al. Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol. 2018;266(1):57. doi:10.1007/S00415-018-9092-4
dc.source.bibliographicCitationGredler V, Mader S, Schanda K, et al. Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases. J Neurol Sci. 2013;328(1-2):77-82. doi:10.1016/j.jns.2013.02.024
dc.source.bibliographicCitationGreenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. http://dx.doi.org/101177/1352458511432896. 2012;18(7):1022-1026. doi:10.1177/1352458511432896
dc.source.bibliographicCitationKim SH, Jeong IH, Hyun JW, et al. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab. JAMA Neurol. 2015;72(9):989-995. doi:10.1001/JAMANEUROL.2015.1276
dc.source.bibliographicCitationLebrun, Christine et al. “Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders.” Neurology and therapy vol. 7,2 (2018): 373-383. doi:10.1007/s40120-018-0101-4
dc.source.bibliographicCitationEvangelopoulos, M E et al. “Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.” Journal of the neurological sciences vol. 372 (2017): 92-96. doi:10.1016/j.jns.2016.11.016
dc.source.bibliographicCitationPellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310-1315. doi:10.1212/WNL.0B013E3182152881
dc.source.bibliographicCitationQuan C, Zhang Bao J, Lu J, et al. The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy. J Neuroimmunol. 2015;282:45-53. doi:10.1016/J.JNEUROIM.2015.03.016
dc.source.bibliographicCitationTahara M, Oeda T, Okada K, et al. Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration. Mult Scler Relat Disord. 2022;60(November 2021):103730. doi:10.1016/j.msard.2022.103730
dc.source.bibliographicCitationTrewin BP, Adelstein S, Spies JM, et al. Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules. Mult Scler Relat Disord. 2020;43. doi:10.1016/J.MSARD.2020.102175
dc.source.bibliographicCitationValentino P, Marnetto F, Granieri L, Capobianco M, Bertolotto A. Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study. Neurol Neuroimmunol NeuroInflammation. 2017;4(2):1-9. doi:10.1212/NXI.0000000000000317
dc.source.bibliographicCitationXiao H, Zeng W, Li L, et al. Retrospective Observation of Low-Dose Rituximab Treatment in Chinese Patients With Neuromyelitis Optica Spectrum Disorders in a Real-World Setting. Front Neurol. 2020;11:537116. doi:10.3389/FNEUR.2020.00642/BIBTEX
dc.source.bibliographicCitationYang, Chun-Sheng et al. “Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica.” Neurology vol. 81,8 (2013): 710-3. doi:10.1212/WNL.0b013e3182a1aac7
dc.source.bibliographicCitationYang Y, Wang C juan, Wang B jie, Zeng Z ling, Guo S gang. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci. 2018;385:192-197. doi:10.1016/J.JNS.2017.12.034
dc.source.bibliographicCitationBruschi N, Malentacchi M, Malucchi S, et al. Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study. Neurol Ther. 2023;12(4):1375-1383. doi:10.1007/S40120-023-00481-W.
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR
dc.subjectMonitoreo de células B
dc.subjectLinfocitos CD19+
dc.subjectCélulas B de memoria CD27 +
dc.subjectCitometría de flujo
dc.subjectNeuromielitis óptica
dc.subjectRecaída
dc.subjectRituximab
dc.subjectRevisión sistemática
dc.subject.keywordB-cell monitoring
dc.subject.keywordCD19+ lymphocytes
dc.subject.keywordCD27+ memory B cells
dc.subject.keywordFlow cytometry
dc.subject.keywordNeuromyelitis optica
dc.subject.keywordRelapse
dc.subject.keywordRituximab
dc.subject.keywordSystematic review
dc.titleEsquemas de rituximab y conteo de linfocitos en pacientes con Neuromielitis óptica: revisión sistemática
dc.title.TranslatedTitleRituximab regimens and lymphocyte counts in patients with neuromyelitis optica: a systematic review
dc.typemasterThesis
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaPre-print
local.department.reportEscuela de Medicina y Ciencias de la Salud
local.regionesBogotá
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
Esquemas_de_rituximab_y_conteo.pdf
Tamaño:
879.17 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Especialización en Neurología